Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program

Ralf Gold, Dusan Stefoski, Krzysztof Selmaj, Eva Havrdova, Christopher Hurst, Joan Holman, Belen Tornesi, Surekha Akella, Peter McCroskery, Ralf Gold, Dusan Stefoski, Krzysztof Selmaj, Eva Havrdova, Christopher Hurst, Joan Holman, Belen Tornesi, Surekha Akella, Peter McCroskery

Abstract

Introduction: Multiple sclerosis (MS) is more common in women and can occur during childbearing years; thus, information on outcomes following exposure to MS therapy during pregnancy is important. No formal studies of daclizumab have been conducted in pregnant women. Here, we report available nonclinical and clinical data on pregnancy outcomes from the daclizumab clinical study program.

Methods: Reproductive and developmental toxicity studies were conducted in cynomolgus monkeys. Reports of pregnancies that occurred during the daclizumab clinical study program through March 9, 2015 were collated and summarized. In the event of pregnancy, daclizumab was discontinued and safety monitoring continued.

Results: Studies in cynomolgus monkeys showed no daclizumab-related effects on maternal well-being, embryo-fetal development, indirect fertility end points, and pre- and postnatal development and growth. Across the clinical study program, 38 pregnancies were reported in 36 daclizumab-exposed women (on treatment ≤6 months from last dose); 20 resulted in live births and four (11%) in spontaneous abortions or miscarriages. One congenital heart defect (complex transposition of great vessels) occurred in one live birth (considered unrelated to daclizumab); daclizumab had been discontinued and intramuscular interferon beta-1a and lisinopril were used at conception. Eight women had an elective termination, two had an ectopic pregnancy, and two were lost to follow-up; two pregnancy outcomes are pending. Six additional pregnancies occurred in five women >6 months after their last daclizumab dose; in one additional pregnancy, exposure was unknown.

Conclusion: Spontaneous abortion rate in daclizumab-exposed women was consistent with early pregnancy loss in the general population (12%-26%). Data on pregnancies exposed to daclizumab do not suggest an increased risk of adverse fetal or maternal outcomes, although the numbers are too small for definitive conclusions. CLINICALTRIALS.

Gov identifiers: NCT00390221, NCT01064401, NCT01462318, NCT00870740, NCT01051349, and NCT01797965.

Funding: Biogen and AbbVie Biotherapeutics Inc.

Keywords: Clinical trials; Daclizumab; Multiple sclerosis; Pregnancy; Teratogenicity.

References

    1. Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev Clin Immunol. 2013;9:683–691. doi: 10.1586/1744666X.2013.811046.
    1. Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013;13:251–260. doi: 10.1586/ern.13.12.
    1. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10:55–67. doi: 10.1007/s13311-012-0147-4.
    1. Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9:394–404. doi: 10.1038/nrneurol.2013.95.
    1. Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H, Finnish Multiple Sclerosis and Pregnancy Study Group Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol. 2008;151:235–243. doi: 10.1111/j.1365-2249.2007.03555.x.
    1. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458–465. doi: 10.1111/j.1365-2567.2008.03027.x.
    1. Brok HP, Tekoppele JM, Hakimi J, et al. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol. 2001;124:134–141. doi: 10.1046/j.1365-2249.2001.01487.x.
    1. Guex-Crosier Y, Raber J, Chan CC, et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 1997;158:452–458.
    1. Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13:472–481. doi: 10.1016/S1474-4422(14)70039-0.
    1. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167–2175. doi: 10.1016/S0140-6736(12)62190-4.
    1. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418–1428. doi: 10.1056/NEJMoa1501481.
    1. Radue E-W, Giovannoni G, Gold R, et al. Long-term efficacy of daclizumab HYP in relapsing-remitting multiple sclerosis: 3 year results from the SELECTED extension study. Presented at 67th Annual Meeting of the Academy of Neurology, 18–25 April 2015; Washington, DC, USA.
    1. Gold R, Giovannoni G, Selmaj K, et al. Long-term safety of daclizumab HYP in patients with relapsing-remitting multiple sclerosis: 3–4 year results from the SELECTED extension study [poster P7.225]. Presented at 67th Annual Meeting of the American Academy of Neurology, 18–25 April 2015, Washington, DC, USA.
    1. Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability of daclizumab HYP in patients with relapsing-remitting multiple sclerosis: an integrated analysis of six clinical studies [poster P554]. Presented at 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 7–10 Oct 2015, Barcelona, Spain.
    1. Pineles BL, Park E, Samet JM. Systematic review and meta-analysis of miscarriage and maternal exposure to tobacco smoke during pregnancy. Am J Epidemiol. 2014;179:807–823. doi: 10.1093/aje/kwt334.
    1. Jarvis P, Srivastav S, Vogelwedde E, Stewart J, Mitchard T, Weinbauer GF. The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations. Birth Defects Res B Dev Reprod Toxicol. 2010;89:175–187.
    1. Tsuchida J, Yoshida T, Sankai T, Yasutomi Y. Maternal behavior of laboratory-born, individually reared long-tailed macaques (Macaca fascicularis) J Am Assoc Lab Anim Sci. 2008;47:29–34.
    1. Delnord M, Blondel B, Zeitlin J. What contributes to disparities in the preterm birth rate in European countries? Curr Opin Obstet Gynecol. 2015;27:133–142. doi: 10.1097/GCO.0000000000000156.
    1. Othman AA, Tran JQ, Tang MT, Dutta S. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet. 2014;53:907–918. doi: 10.1007/s40262-014-0159-9.
    1. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011;17:423–430. doi: 10.1177/1352458510394610.
    1. Tomczyk S, Sperling B. Pregnancy outcomes in patients exposed to intramuscular interferon beta-1a (IM IFNβ-1a) Neurology. 2013;80(S30):006.
    1. Romero RS, Lunzmann C, Bugge JP. Pregnancy outcomes in patients exposed to interferon beta-1b. J Neurol Neurosurg Psychiatry. 2015;86:587–589. doi: 10.1136/jnnp-2014-308113.
    1. Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;12:124. doi: 10.1186/1471-2377-12-124.
    1. Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21:198–205. doi: 10.1177/1352458514546790.
    1. Cristiano L, Friend S, Bozic C, Bloomgren G. Evaluation of pregnancy outcomes from the TYSABRI® (Natalizumab) pregnancy exposure registry. Neurology. 2013;80(P02):127.
    1. Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674–680. doi: 10.1212/WNL.0000000000000137.
    1. Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014;3:133–138. doi: 10.1007/s40120-014-0020-y.
    1. Gold R, Phillips T, Havrdova E. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 2015;4:93–104. doi: 10.1007/s40120-015-0033-1.
    1. McCombe P, Achiron A, Giovannoni G, et al. Pregnancy outcomes in the alemtuzumab multiple sclerosis clinical development program. Presented at the Joint ACTRIMS-ECTRIMS Meeting, 10–13 Oct 2014, Boston, MA, USA.
    1. Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 2015;29:207–220. doi: 10.1007/s40263-015-0238-y.
    1. Diao L, Hang Y, Othman AA, Nestorov I, Tran JQ. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers and subjects with multiple sclerosis: analysis of phase I–III clinical trials [published online 12 Feb 2016]. Clin Pharmacokinet. doi:10.1007/s40262-016-0366-7.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren